

Pneumococcal Vaccine Market Size, Share & Trends Analysis Report By Vaccine Type, By Product (Pevnar 13, VAXNEUVANCE, PNEUMOSIL), By End-use (Public Sector, Private Sector), By Region, And Segment Forecasts, 2024 - 2030

<https://marketpublishers.com/r/P340B662F660EN.html>

Date: May 2024

Pages: 125

Price: US\$ 5,950.00 (Single User License)

ID: P340B662F660EN

Abstracts

This report can be delivered to the clients within Immediate

Pneumococcal Vaccine Market Growth & Trends

The global pneumococcal vaccine market size is anticipated to reach USD 12.19 billion by 2030, registering a CAGR of 6.21% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing prevalence of target diseases. Pneumococcus is the main cause of invasive disease, pneumonia, and upper respiratory tract infection and can lead to severe sequelae such as deafness, paralysis, intellectual disability, and other serious complications. For instance, in September 2023, the World Health Organization (WHO) estimated that *Streptococcus pneumoniae* is responsible for over 300,000 deaths annually among children under the age of 5 worldwide. The majority of these fatalities occur in developing nations. Globally, *S. pneumoniae* is the primary cause of pneumonia-related deaths, surpassing all other causes combined. The highest number of deaths due to this bacterium is observed in countries located in Africa and Asia.

Increasing government awareness programs regarding pneumonia immunization fuels the market growth. For instance, in September 2023, a survey conducted in September and October 2022 found that there's a need to extend the recommendations for the new 20-valent pneumococcal conjugate vaccine (PCV20) to adults who previously received the 13-valent pneumococcal conjugate vaccine (PCV13). The survey showed that

healthcare providers need to be more aware of and implement pneumococcal vaccination recommendations better. After considering these findings, the Advisory Committee on Immunization Practices (ACIP) agreed to update the recommendations in late October 2022.

Moreover, product launches by key players is contributing to market growth. For instance, In October 2022, Merck & Co., Inc. received the European Commission's (EC) approval for its Vaxneuvance, a pneumococcal vaccine. The approval allows product marketing in 27 European Union (EU) member states and Iceland, Norway, & Lichtenstein. Moreover, in September 2021, Minhai Biotechnology Co. Ltd. received approval from the National Medical Products Administration, China, for its 13-valent vaccine.

Growing R&D for developing novel vaccines boosting the growth of the market. In March 2024, SK Bioscience's announced expansion of its L House vaccine manufacturing facility in South Korea indicates a proactive approach to enhancing vaccine production capacity. This expansion, driven by the joint development of the pneumococcal conjugate vaccine candidate GBP410 with Sanofi, follows positive Phase 2 clinical trial results. SK Bioscience plans to conduct a global Phase 3 clinical trial in 2027, demonstrating a commitment to collaboration and global vaccine development.

Pneumococcal Vaccine Market Report Highlights

Based on type, Pneumococcal Conjugate Vaccine (PCV) segment led the market and is anticipated to grow at the fastest growth over the forecast period. PCV helps protect against pneumococcal disease, a leading cause of death among children under 5 years old

Based on product, Prevnar 13 dominated the market and is expected to grow significantly during the forecast period. The vaccines under the Prevnar brand include Prevnar 13 and Prevnar 20. These are pneumococcal conjugate vaccines (PCVs) designed to protect against pneumococcal disease

Based on end-use, the public sector led the market and is anticipated to grow at the fastest CAGR over the forecast period. The dominance of the public sector in the end use of pneumococcal vaccines, including hospitals, clinics, and healthcare facilities, can be attributed to several factors. These factors include the high prevalence of diseases, government initiatives to increase vaccination coverage

North America dominated the market owing to factors such as advanced healthcare infrastructure, rising prevalence of target diseases, and favorable regulatory environment

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
 - 1.2.1. Vaccine Type
 - 1.2.2. Product
 - 1.2.3. End Use
 - 1.2.4. Regional scope
 - 1.2.5. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
 - 1.4.1. Purchased database
 - 1.4.2. GVR's internal database
 - 1.4.3. Secondary sources
 - 1.4.4. Primary research
 - 1.4.5. Details of primary research
 - 1.4.5.1. Data for primary interviews in North America
 - 1.4.5.2. Data for primary interviews in Europe
 - 1.4.5.3. Data for primary interviews in Asia Pacific
 - 1.4.5.4. Data for primary interviews in Latin America
 - 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
 - 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
 - 1.7.1. Commodity flow analysis (Model 1)
 - 1.7.2. Approach 1: Commodity flow approach
 - 1.7.3. Volume price analysis (Model 2)
 - 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Outlook
- 2.2. Segment Outlook

- 2.2.1. Vaccine Type and Product outlook
- 2.2.2. End Use outlook
- 2.2.3. Regional outlook
- 2.3. Competitive Insights

CHAPTER 3. PNEUMOCOCCAL VACCINE MARKET VARIABLES, TRENDS & SCOPE

- 3.1. Market Lineage Outlook
 - 3.1.1. Parent market outlook
 - 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
 - 3.2.1. Market driver analysis
 - 3.2.1.1. Increasing prevalence of target disease
 - 3.2.1.2. Rising awareness and favorable government initiatives
 - 3.2.1.3. Growing R&D for developing novel vaccines
 - 3.2.2. Market restraint analysis
 - 3.2.2.1. Supply chain and vaccine shortage challenges
 - 3.2.2.2. Vaccine hesitancy and public awareness
- 3.3. Pneumococcal Vaccine Market Analysis Tools
 - 3.3.1. Industry Analysis - Porter's
 - 3.3.1.1. Supplier power
 - 3.3.1.2. Buyer power
 - 3.3.1.3. Substitution threat
 - 3.3.1.4. Threat of new entrant
 - 3.3.1.5. Competitive rivalry
 - 3.3.2. PESTEL Analysis
 - 3.3.2.1. Political landscape
 - 3.3.2.2. Technological landscape
 - 3.3.2.3. Economic landscape
 - 3.3.3. Pricing Analysis
 - 3.3.4. Volume Analysis (Instruments)

CHAPTER 4. PNEUMOCOCCAL VACCINE MARKET: VACCINE TYPE ESTIMATES & TREND ANALYSIS

- 4.1. Global Pneumococcal Vaccine Market: Vaccine Type Dashboard
- 4.2. Global Pneumococcal Vaccine Market: Vaccine Type Movement Analysis
- 4.3. Global Pneumococcal Vaccine Market by Vaccine Type, Revenue

4.4. Pneumococcal Conjugate Vaccine

4.4.1. Pneumococcal Conjugate Vaccine market estimates and forecasts 2018 to 2030 (USD Million)

4.5. Pneumococcal Polysaccharide Vaccine

4.5.1. Pneumococcal Polysaccharide Vaccine market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 5. PNEUMOCOCCAL VACCINE MARKET: PRODUCT ESTIMATES & TREND ANALYSIS

5.1. Global Pneumococcal Vaccine Market: Product Dashboard

5.2. Global Pneumococcal Vaccine Market: Product Movement Analysis

5.3. Global Pneumococcal Vaccine Market by Product, Revenue

5.4. Prevnar

5.4.1. Prevnar 13 market estimates and forecasts 2018 to 2030 (USD Million)

5.5. Synflorix

5.5.1. Synflorix market estimates and forecasts 2018 to 2030 (USD Million)

5.6. Pneumovax

5.6.1. Pneumovax 23 market estimates and forecasts 2018 to 2030 (USD Million)

5.7. VAXNEUVANCE

5.7.1. VAXNEUVANCE market estimates and forecasts 2018 to 2030 (USD Million)

5.8. PNEUMOSIL

5.8.1. PNEUMOSIL market estimates and forecasts 2018 to 2030 (USD Million)

5.9. Other Products

5.9.1. Other Products market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 6. PNEUMOCOCCAL VACCINE MARKET: END USE ESTIMATES & TREND ANALYSIS

6.1. Global Pneumococcal Vaccine Market: End Use Dashboard

6.2. Global Pneumococcal Vaccine Market: End Use Movement Analysis

6.3. Global Pneumococcal Vaccine Market by End Use, Revenue

6.4. Public Sector

6.4.1. Public Sector market estimates and forecasts 2018 to 2030 (USD Million)

6.5. Private Sector

6.5.1. Private Sector market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 7. PNEUMOCOCCAL VACCINE MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY VACCINE TYPE, PRODUCT, AND END USE

7.1. Regional Dashboard

7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:

7.3. North America

7.3.1. U.S.

7.3.1.1. Key country dynamics

7.3.1.2. Target disease prevalence

7.3.1.3. Regulatory framework/ reimbursement structure

7.3.1.4. Competitive scenario

7.3.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)

7.3.2. Canada

7.3.2.1. Key country dynamics

7.3.2.2. Target disease prevalence

7.3.2.3. Regulatory framework/ reimbursement structure

7.3.2.4. Competitive scenario

7.3.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)

7.4. Europe

7.4.1. UK

7.4.1.1. Key country dynamics

7.4.1.2. Target disease prevalence

7.4.1.3. Regulatory framework/ reimbursement structure

7.4.1.4. Competitive scenario

7.4.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)

7.4.2. Germany

7.4.2.1. Key country dynamics

7.4.2.2. Target disease prevalence

7.4.2.3. Regulatory framework/ reimbursement structure

7.4.2.4. Competitive scenario

7.4.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)

7.4.3. France

7.4.3.1. Key country dynamics

7.4.3.2. Target disease prevalence

7.4.3.3. Regulatory framework/ reimbursement structure

7.4.3.4. Competitive scenario

7.4.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)

7.4.4. Italy

7.4.4.1. Key country dynamics

7.4.4.2. Target disease prevalence

7.4.4.3. Regulatory framework/ reimbursement structure

7.4.4.4. Competitive scenario

7.4.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)

7.4.5. Spain

7.4.5.1. Key country dynamics

7.4.5.2. Target disease prevalence

7.4.5.3. Regulatory framework/ reimbursement structure

7.4.5.4. Competitive scenario

7.4.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)

7.4.6. Norway

7.4.6.1. Key country dynamics

7.4.6.2. Target disease prevalence

7.4.6.3. Regulatory framework/ reimbursement structure

7.4.6.4. Competitive scenario

7.4.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)

7.4.7. Sweden

7.4.7.1. Key country dynamics

7.4.7.2. Target disease prevalence

7.4.7.3. Regulatory framework/ reimbursement structure

7.4.7.4. Competitive scenario

7.4.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)

7.4.8. Denmark

7.4.8.1. Key country dynamics

7.4.8.2. Target disease prevalence

7.4.8.3. Regulatory framework/ reimbursement structure

7.4.8.4. Competitive scenario

7.4.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)

7.5. Asia Pacific

7.5.1. Japan

7.5.1.1. Key country dynamics

7.5.1.2. Target disease prevalence

7.5.1.3. Regulatory framework/ reimbursement structure

7.5.1.4. Competitive scenario

7.5.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)

7.5.2. China

7.5.2.1. Key country dynamics

7.5.2.2. Target disease prevalence

7.5.2.3. Regulatory framework/ reimbursement structure

7.5.2.4. Competitive scenario

7.5.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)

7.5.3. India

7.5.3.1. Key country dynamics

7.5.3.2. Target disease prevalence

7.5.3.3. Regulatory framework/ reimbursement structure

7.5.3.4. Competitive scenario

7.5.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)

7.5.4. Australia

7.5.4.1. Key country dynamics

7.5.4.2. Target disease prevalence

7.5.4.3. Regulatory framework/ reimbursement structure

7.5.4.4. Competitive scenario

7.5.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)

7.5.5. South Korea

7.5.5.1. Key country dynamics

7.5.5.2. Target disease prevalence

7.5.5.3. Regulatory framework/ reimbursement structure

7.5.5.4. Competitive scenario

7.5.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)

7.5.6. Thailand

7.5.6.1. Key country dynamics

7.5.6.2. Target disease prevalence

7.5.6.3. Regulatory framework/ reimbursement structure

7.5.6.4. Competitive scenario

7.5.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)

7.6. Latin America

7.6.1. Brazil

7.6.1.1. Key country dynamics

7.6.1.2. Target disease prevalence

7.6.1.3. Regulatory framework/ reimbursement structure

7.6.1.4. Competitive scenario

7.6.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)

7.6.2. Mexico

7.6.2.1. Key country dynamics

7.6.2.2. Target disease prevalence

7.6.2.3. Regulatory framework/ reimbursement structure

7.6.2.4. Competitive scenario

7.6.2.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)

7.6.3. Argentina

7.6.3.1. Key country dynamics

- 7.6.3.2. Target disease prevalence
- 7.6.3.3. Regulatory framework/ reimbursement structure
- 7.6.3.4. Competitive scenario
- 7.6.3.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)

7.7. MEA

7.7.1. South Africa

- 7.7.1.1. Key country dynamics
- 7.7.1.2. Target disease prevalence
- 7.7.1.3. Regulatory framework/ reimbursement structure
- 7.7.1.4. Competitive scenario
- 7.7.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)

7.7.2. Saudi Arabia

- 7.7.2.1. Key country dynamics
- 7.7.2.2. Target disease prevalence
- 7.7.2.3. Regulatory framework/ reimbursement structure
- 7.7.2.4. Competitive scenario
- 7.7.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)

7.7.3. UAE

- 7.7.3.1. Key country dynamics
- 7.7.3.2. Target disease prevalence
- 7.7.3.3. Regulatory framework/ reimbursement structure
- 7.7.3.4. Competitive scenario
- 7.7.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)

7.7.4. Kuwait

- 7.7.4.1. Key country dynamics
- 7.7.4.2. Target disease prevalence
- 7.7.4.3. Regulatory framework/ reimbursement structure
- 7.7.4.4. Competitive scenario
- 7.7.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 8. COMPETITIVE LANDSCAPE

8.1. Recent Developments & Impact Analysis, By Key Market Participants

8.2. Company/Competition Categorization

8.3. Vendor Landscape

- 8.3.1. List of key distributors and channel partners
- 8.3.2. Key customers
- 8.3.3. Key company market share analysis, 2023
- 8.3.4. Serum Institute of India Pvt. Ltd.

- 8.3.4.1. Company overview
- 8.3.4.2. Financial performance
- 8.3.4.3. Product benchmarking
- 8.3.4.4. Strategic initiatives
- 8.3.5. CSL
 - 8.3.5.1. Company overview
 - 8.3.5.2. Financial performance
 - 8.3.5.3. Product benchmarking
 - 8.3.5.4. Strategic initiatives
- 8.3.6. Sanofi
 - 8.3.6.1. Company overview
 - 8.3.6.2. Financial performance
 - 8.3.6.3. Product benchmarking
 - 8.3.6.4. Strategic initiatives
- 8.3.7. GSK plc
 - 8.3.7.1. Company overview
 - 8.3.7.2. Financial performance
 - 8.3.7.3. Product benchmarking
 - 8.3.7.4. Strategic initiatives
- 8.3.8. Merck & Co., Inc.
 - 8.3.8.1. Company overview
 - 8.3.8.2. Financial performance
 - 8.3.8.3. Product benchmarking
 - 8.3.8.4. Strategic initiatives
- 8.3.9. Pfizer Inc.
 - 8.3.9.1. Company overview
 - 8.3.9.2. Financial performance
 - 8.3.9.3. Product benchmarking
 - 8.3.9.4. Strategic initiatives
- 8.3.10. Walvax Biotechnology Co., Ltd
 - 8.3.10.1. Company overview
 - 8.3.10.2. Financial performance
 - 8.3.10.3. Product benchmarking
 - 8.3.10.4. Strategic initiatives
- 8.3.11. Beijing Minhai Biotechnology Co.,Ltd (Subsidiary of Shenzhen Kangtai Biological Products Co. Ltd.)
 - 8.3.11.1. Company overview
 - 8.3.11.2. Financial performance
 - 8.3.11.3. Product benchmarking

8.3.11.4. Strategic initiatives

List Of Tables

LIST OF TABLES

Table 1 List of abbreviation

Table 2 North America Pneumococcal Vaccine Market, 2018 - 2030 (USD Million)

Table 3 North America Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)

Table 4 North America Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)

Table 5 North America Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)

Table 6 U.S. Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)

Table 7 U.S. Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)

Table 8 U.S. Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)

Table 9 Canada Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)

Table 10 Canada Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)

Table 11 Canada Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)

Table 12 Europe Pneumococcal Vaccine Market, by Region, 2018 - 2030 (USD Million)

Table 13 Europe Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)

Table 14 Europe Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)

Table 15 Europe Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)

Table 16 Germany Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)

Table 17 Germany Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)

Table 18 Germany Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)

Table 19 UK Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)

Table 20 UK Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)

Table 21 UK Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)

Table 22 France Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)

Table 23 France Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)

Table 24 France Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)

Table 25 Italy Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)

Table 26 Italy Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)

Table 27 Italy Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)

Table 28 Spain Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)

Table 29 Spain Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)

Table 30 Spain Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)

Table 31 Denmark Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)

Table 32 Denmark Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)

Table 33 Denmark Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)

Table 34 Sweden Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)

Table 35 Sweden Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)

Table 36 Sweden Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)

Table 37 Norway Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)

Table 38 Norway Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)

Table 39 Norway Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)

Table 40 Asia Pacific Pneumococcal Vaccine Market, by Region, 2018 - 2030 (USD Million)

Table 41 Asia Pacific Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)

Table 42 Asia Pacific Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)

Table 43 Asia Pacific Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)

Table 44 China Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)

Million)

Table 45 China Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)

Table 46 China Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)

Table 47 Japan Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)

Table 48 Japan Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)

Table 49 Japan Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)

Table 50 India Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)

Table 51 India Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)

Table 52 India Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)

Table 53 South Korea Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)

Table 54 South Korea Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)

Table 55 South Korea Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)

Table 56 Australia Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)

Table 57 Australia Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)

Table 58 Australia Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)

Table 59 Thailand Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)

Table 60 Thailand Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)

Table 61 Thailand Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)

Table 62 Latin America Pneumococcal Vaccine Market, by Region, 2018 - 2030 (USD Million)

Table 63 Latin America Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)

Table 64 Latin America Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)

Table 65 Latin America Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)

Table 66 Brazil Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)

- Table 67 Brazil Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
- Table 68 Brazil Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
- Table 69 Mexico Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
- Table 70 Mexico Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
- Table 71 Mexico Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
- Table 72 Argentina Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
- Table 73 Argentina Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
- Table 74 Argentina Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
- Table 75 MEA Pneumococcal Vaccine Market, by Region, 2018 - 2030 (USD Million)
- Table 76 MEA Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
- Table 77 MEA Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
- Table 78 MEA Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
- Table 79 South Africa Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
- Table 80 South Africa Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
- Table 81 South Africa Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
- Table 82 Saudi Arabia Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
- Table 83 Saudi Arabia Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
- Table 84 Saudi Arabia Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
- Table 85 UAE Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
- Table 86 UAE Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
- Table 87 UAE Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)
- Table 88 Kuwait Pneumococcal Vaccine Market, by Vaccine Type, 2018 - 2030 (USD Million)
- Table 89 Kuwait Pneumococcal Vaccine Market, by Product, 2018 - 2030 (USD Million)
- Table 90 Kuwait Pneumococcal Vaccine Market, by End Use, 2018 - 2030 (USD Million)

List Of Figures

LIST OF FIGURES

- Fig. 1 Pneumococcal vaccines market segmentation
- Fig. 2 Market research process
- Fig. 3 Data triangulation techniques
- Fig. 4 Primary research pattern
- Fig. 5 Value chain based sizing & forecasting
- Fig. 6 QFD modelling for market share assessment
- Fig. 7 Market formulation & validation
- Fig. 8 Market snapshot
- Fig. 9 Vaccine type and product segment snapshot
- Fig. 10 End-use segment snapshot
- Fig. 11 Competitive landscape snapshot
- Fig. 12 Parent market (USD billion)
- Fig. 13 Market dynamics
- Fig. 14 Porter's five forces analysis
- Fig. 15 PESTLE analysis
- Fig. 16 Pneumococcal vaccine market: Vaccine type outlook and key takeaways
- Fig. 17 Pneumococcal vaccine market: Vaccine type movement analysis
- Fig. 18 Pneumococcal Conjugate Vaccine (PCV) market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 19 Pneumococcal Polysaccharide Vaccine (PPV) market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 20 Pneumococcal vaccine market: Product outlook and key takeaways
- Fig. 21 Pneumococcal vaccine market: Product movement analysis
- Fig. 22 Prevnar market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 23 Synflorix market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 24 Pneumovax 23 market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 25 VAXNEUVANCE market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 26 PNEUMOSIL market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 27 Other products market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 28 Pneumococcal vaccine market: End-use outlook and key takeaways
- Fig. 29 Pneumococcal vaccine market: End-use movement analysis
- Fig. 30 Public sector market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 31 Private sector market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 32 Pneumococcal vaccine market revenue, by region, 2023 & 2030 (USD Million)

Fig. 33 Regional marketplace: Key takeaways

Fig. 34 Regional marketplace: Key takeaways

Fig. 35 North America pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 36 Key country dynamics

Fig. 37 U.S. pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 39 Key country dynamics

Fig. 40 Canada pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 41 Vaccine testing and approval process in Canada

Fig. 42 Europe pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 43 Key country dynamics

Fig. 44 UK pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 45 Key country dynamics

Fig. 46 Germany pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 47 Key country dynamics

Fig. 48 France pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 49 Key country dynamics

Fig. 50 Spain pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 51 Key country dynamics

Fig. 52 Italy pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 53 Key country dynamics

Fig. 54 Denmark pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 55 Key country dynamics

Fig. 56 Sweden pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 57 Key country dynamics

Fig. 58 Norway pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 59 Rest of Europe pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 60 Asia Pacific pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 61 Key country dynamics

Fig. 62 Japan pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 63 Key country dynamics

Fig. 64 China Pneumococcal Vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 65 China regulatory details

Fig. 66 Key country dynamics

Fig. 67 India pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 68 Key country dynamics

Fig. 69 Australia pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 70 Key country dynamics

Fig. 71 Thailand pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 72 Key country dynamics

Fig. 73 South Korea pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 74 South Korea reimbursement scenario

Fig. 75 Rest of Asia Pacific pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 76 Latin America pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 77 Key country dynamics

Fig. 78 Brazil pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 79 Brazil regulation details

Fig. 80 Brazil reimbursement scenario

Fig. 81 Key country dynamics

Fig. 82 Mexico pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 84 Key country dynamics

Fig. 85 Argentina pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 86 Argentina regulatory framework

Fig. 87 Rest of Latin America pneumococcal vaccine market estimates and forecasts,

2018 - 2030 (USD Million)

Fig. 88 MEA pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 89 Key country dynamics

Fig. 90 South Africa pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 91 Key country dynamics

Fig. 92 Saudi Arabia pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 93 Key country dynamics

Fig. 94 UAE pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 95 Key country dynamics

Fig. 96 Kuwait pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 97 Rest of MEA pneumococcal vaccine market estimates and forecasts, 2018 - 2030 (USD Million)

I would like to order

Product name: Pneumococcal Vaccine Market Size, Share & Trends Analysis Report By Vaccine Type, By Product (Pevnar 13, VAXNEUVANCE, PNEUMOSIL), By End-use (Public Sector, Private Sector), By Region, And Segment Forecasts, 2024 - 2030

Product link: <https://marketpublishers.com/r/P340B662F660EN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P340B662F660EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970